Welcome to our dedicated page for WW International news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on WW International stock.
WW International, Inc. (WeightWatchers), trading under the symbol WW, is frequently in the news for developments in science-backed weight management, clinical programs, and digital health innovation. Company announcements emphasize its role as a global leader in weight health, combining behavioral programs, clinical care, GLP‑1 medications when appropriate, and technology-enabled support.
News about WeightWatchers often covers updates to its integrated GLP‑1 platform, including the WeightWatchers Med+ program and the GLP‑1 Success behavioral support experience. Releases have highlighted access to FDA‑approved GLP‑1 treatments, such as an oral formulation of Wegovy, and the company’s positioning as a NovoCare Recognized Care Provider. These stories focus on how WeightWatchers pairs medication access with evidence‑based nutrition, coaching, and community to improve outcomes.
Investors and observers will also find coverage of new product and feature launches within the WeightWatchers app, such as the Weight Health Score, AI Body Scanner, fitness content partnerships, and configurable Modes that adjust support as members move from weight loss to maintenance. Additional news items include the launch of specialized programs like WeightWatchers for Menopause, the publication of WeightWatchers for Business annual results, collaborations with partners like Amazon Pharmacy, and the introduction of the WeightWatchers Awards for health and wellness products.
On this news page, readers can track earnings announcements, conference participation, leadership appointments, and strategic initiatives related to WeightWatchers’ transformation in the GLP‑1 era. For those following WW stock or the broader weight health sector, the news feed provides a centralized view of how the company is evolving its behavioral and clinical businesses, expanding partnerships, and refining its global weight management platform.
Weight Watchers (NASDAQ: WW) will participate in investor conferences in January 2026, including the ICR Conference in Orlando on January 12–13 and a virtual fireside chat at the CJS Securities 26th Annual New Ideas for the New Year on January 14 at 11:00 a.m. ET.
The January 14 fireside chat will be available via live audio webcast at corporate.ww.com under Events and Presentations, with a replay accessible for at least 90 days. Weight Watchers said it will host investor meetings during these events.
Weight Watchers described its offering as an integrated, science-backed weight management system for the GLP-1 era, combining clinical interventions, access to GLP-1 medications when clinically appropriate, technology, and coaching. For investor inquiries, contacts were provided.
Weight Watchers (NASDAQ: WW) announced on January 5, 2026 that its Med+ integrated GLP-1 platform will offer access to FDA‑approved oral Wegovy® pill, expanding options beyond injectable therapies. The program pairs medication access with behavioral coaching, clinician care, and digital tools.
Weight Watchers said Med+ members can access the oral Wegovy pill starting at $149 per month. Internal member analyses reported that engaged Med+ members on GLP-1s lost 61.3% more body weight at 1 month and 29.1% more at 12 months versus GLP-1 users without behavioral support. The company is a NovoCare® Recognized Care Provider and emphasized combining medication with structured support to improve real-world outcomes.
Weight Watchers (NASDAQ: WW) launched a fully integrated platform for the GLP-1 era on Dec. 16, 2025, combining a medical program, behavioral support, coaching, community, and new digital tools.
Key elements include Weight Watchers Med+ (board-certified physicians prescribing GLP-1s for eligible members), the standalone GLP-1 Success Program, a redesigned app with Weight Health Score, an AI Body Scanner, premium fitness content, and flexible Modes (All-In, Lose, Maintain). The rollout begins Dec. 26, 2025.
WeightWatchers (Nasdaq: WW) reported Q3 fiscal 2025 results for the quarter ended September 30, 2025: End of period subscribers 3.0 million (including Clinical subscribers 124k), Total revenues $172 million, and Clinical subscription revenue $26 million, up 35.3% YoY. The company recorded a net loss of $58 million (net loss margin 33.4%), which included a $53 million income tax charge. Adjusted EBITDA was $43 million (margin 24.9%).
Balance sheet improved: total debt reduced by >70% (~$1.1 billion) and cash rose to $170 million. Management narrowed fiscal 2025 guidance to Revenues $695–700M and Adjusted EBITDA $145–150M.
WW (NASDAQ: WW) will release third quarter 2025 results for the period ended September 30, 2025 before market open on Thursday, November 6, 2025.
The company will host a conference call at 8:30 a.m. ET on November 6, 2025, with a live webcast available on the company's investor site at corporate.ww.com under Events and Presentations. A replay of the webcast will be available on the site for at least 90 days.
WeightWatchers (NASDAQ: WW) announced a collaboration with Amazon Pharmacy on October 20, 2025 to speed medication access for WeightWatchers Clinic members.
Key features include real-time medication availability, automatic manufacturer-sponsored savings at checkout, and fast home delivery including free two-day shipping for Prime and same-day delivery where eligible. The integration uses Amazon’s pharmacy infrastructure (licensed pharmacists, robotic vial-filling, smart routing) to simplify prescriptions for GLP-1s and other weight-management medications.
The release cites a WeightWatchers Clinic study showing members lost 21% body weight at 12 months, and says the partnership aims to pair medication access with the company’s clinical programs and coaching.
WeightWatchers (NASDAQ: WW) launched RxFlexFund on October 17, 2025, a new employer benefit model to expand GLP-1 access by combining direct manufacturer pricing, employer subsidies, and WeightWatchers clinical and behavioral support.
Employers pay for WeightWatchers Clinic and subsidize medication costs at a set rate of 25%–75%. Members receive FDA‑approved GLP‑1 prescriptions with obesity‑trained clinicians, nutrition and behavior programs, and registered dietitians. Company cites a 20% reduction in annual healthcare expenses linked to weight loss and a reported 46% boost in work‑related quality of life in a 6‑month trial (n=180).
WeightWatchers (NASDAQ: WW) published its 2025 WeightWatchers for Business Annual Report on Oct 15, 2025, highlighting measurable employer health outcomes and economic impact.
Key findings: 21% average weight loss at 12 months for WW Clinic patients prescribed GLP-1s; 46% improvement in work-related quality of life; 0.9-point HbA1c reduction at six months in a diabetes trial; 55% monthly engagement and 90% client satisfaction. Report notes ROI projections up to 4X and states some studies are company-funded or manuscripts under review.
WeightWatchers (NASDAQ: WW) has launched a pioneering menopause program featuring Queen Latifah as its first official spokeswoman. The comprehensive program, WeightWatchers for Menopause, combines medical care, nutrition support, and community resources to support women through perimenopause to post-menopause.
The program has demonstrated significant results, with menopausal women losing nearly 4x more weight than those managing independently. Members using WeightWatchers Clinic achieved an average 18.6% body weight loss (40.1 lbs) in one year. Research from Mayo Clinic showed postmenopausal women receiving hormone therapy with GLP-1 semaglutide achieved 30% greater weight loss compared to GLP-1 alone.
WeightWatchers (NASDAQ: WW) has appointed Alejandro Bethlen as Executive Vice President, International, to lead the company's global expansion efforts. Bethlen brings over two decades of experience in scaling consumer, e-commerce, and marketplace businesses worldwide, previously serving as Chief Merchandising Officer at Zooplus SE and holding senior roles at Amazon.
This strategic appointment comes as part of WeightWatchers' broader transformation, which includes recent leadership additions such as Dr. Kim Boyd as Chief Medical Officer, Uta Knablein as Chief Product Officer, and Julie Rice as Chief Experience Officer. The company aims to leverage its 50+ years of international presence and scientific expertise to expand its reach in global markets.
FAQ
What is the current stock price of WW International (WW)?
What is the market cap of WW International (WW)?
